Tissue selective drug delivery utilizing carrier-mediated transport systems.

Area of Science:

• Pharmacology
• Biotechnology
• Drug Delivery Systems

Background:

• Targeted drug delivery aims to improve therapeutic efficacy and reduce side effects.
• Specialized transporters in target cells offer a promising avenue for achieving tissue selectivity.
• Understanding transporter expression and function is crucial for designing effective drug delivery strategies.

Purpose of the Study:

• To demonstrate successful examples of tissue-selective drug delivery using specific transporters.
• To highlight the potential of transporter-mediated delivery for various therapeutic agents and target tissues.
• To provide a foundation for developing novel drug delivery systems.

Main Methods:

• Utilizing H+/oligopeptide transporters (Pept1) for oral delivery of beta-lactam antibiotics and dipeptides.
• Employing newly discovered H+/oligopeptide transporters for tumor-specific delivery of oligopeptides.
• Leveraging H+/monocarboxylate and organic anion transporters for oral and hepatic delivery of pravastatin.
• Investigating transporter-mediated lung-selective delivery and P-glycoprotein efflux for HSR-903.

Main Results:

• Successful oral delivery of beta-lactam antibiotics and a novel dipeptide via Pept1.
• Demonstrated tumor cell-specific uptake of oligopeptides using novel transporters in HT-1080 cells.
• Achieved oral and hepatic delivery of pravastatin through specific intestinal and liver transporters.
• Showcased lung-selective delivery and brain-avoidance of a quinolone antibacterial via transporter mechanisms.

Conclusions:

• Transporter-mediated drug delivery is a viable strategy for achieving tissue selectivity.
• Specific transporters can be exploited for targeted delivery to the intestine, tumors, liver, and lungs.
• This approach holds significant potential for improving drug efficacy and safety profiles.